The psychedelic medicine sector has spent years building momentum on the back of compelling clinical narratives. But as 2026 unfolds, the conversation is evolving into something more technical, and arguably more consequential. The focus is shifting away from experience driven therapy toward a deeper understanding of how specific receptor pathways and neuroplastic mechanisms can be targeted to treat psychiatric disease.
